BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ong JJY, Wei DY, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs 2018;78:411-37. [PMID: 29396834 DOI: 10.1007/s40265-018-0865-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Marmura MJ, Kumpinsky AS. Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders. CNS Drugs 2018;32:735-46. [PMID: 30073584 DOI: 10.1007/s40263-018-0555-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Qubty W, Patniyot I. Migraine Pathophysiology. Pediatric Neurology 2020;107:1-6. [DOI: 10.1016/j.pediatrneurol.2019.12.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Seminowicz DA, Burrowes SAB, Kearson A, Zhang J, Krimmel SR, Samawi L, Furman AJ, Keaser ML, Gould NF, Magyari T, White L, Goloubeva O, Goyal M, Peterlin BL, Haythornthwaite JA. Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes. Pain 2020;161:1837-46. [PMID: 32701843 DOI: 10.1097/j.pain.0000000000001860] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
4 Martins-Oliveira M, Tavares I, Goadsby PJ. Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits. Brain Res 2021;1770:147629. [PMID: 34428465 DOI: 10.1016/j.brainres.2021.147629] [Reference Citation Analysis]
5 Rea BJ, Wattiez AS, Waite JS, Castonguay WC, Schmidt CM, Fairbanks AM, Robertson BR, Brown CJ, Mason BN, Moldovan-Loomis MC, Garcia-Martinez LF, Poolman P, Ledolter J, Kardon RH, Sowers LP, Russo AF. Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine. Pain 2018;159:2306-17. [PMID: 29994995 DOI: 10.1097/j.pain.0000000000001337] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
6 Holton CM, Strother LC, Dripps I, Pradhan AA, Goadsby PJ, Holland PR. Acid-sensing ion channel 3 blockade inhibits durovascular and nitric oxide-mediated trigeminal pain. Br J Pharmacol 2020;177:2478-86. [PMID: 31975427 DOI: 10.1111/bph.14990] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wattiez AS, Wang M, Russo AF. CGRP in Animal Models of Migraine. Handb Exp Pharmacol 2019;255:85-107. [PMID: 30689086 DOI: 10.1007/164_2018_187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
8 Broessner G, Reuter U, Bonner JH, Dodick DW, Hallström Y, Picard H, Zhang F, Lenz RA, Klatt J, Mikol DD. The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response. Headache 2020;60:2026-40. [PMID: 32851644 DOI: 10.1111/head.13929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Gelfand AA, Goadsby PJ. Cluster Headache and Calcitonin Gene-Related Peptide-More on Quantum Therapeutics in Headache Medicine. JAMA Neurol 2018;75:1179-80. [PMID: 29987331 DOI: 10.1001/jamaneurol.2018.1428] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q, Skljarevski V, Aurora SK. Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. J Neurol Neurosurg Psychiatry 2019;90:939-44. [PMID: 31004075 DOI: 10.1136/jnnp-2018-320242] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
11 Thiele A, Strauß S, Angermaier A, Kronenbuerger M, Fleischmann R. Translation and validation of an extended German version of ID Migraine ™ as a migraine screening tool. Cephalalgia Reports 2020;3:251581632096277. [DOI: 10.1177/2515816320962773] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Yang CP, Lee CF, Dell'Agnello G, Hundemer HP, Lipsius S, Wang SJ. Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine. Curr Med Res Opin 2020;36:1653-66. [PMID: 32845740 DOI: 10.1080/03007995.2020.1815181] [Reference Citation Analysis]
13 [DOI: 10.1101/19004069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Orlando V, Mucherino S, Monetti VM, Trama U, Menditto E. Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study. BMJ Open 2020;10:e038972. [PMID: 33148742 DOI: 10.1136/bmjopen-2020-038972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ng CYH, Tan BYQ, Teo YN, Teo YH, Syn NLX, Leow AST, Ho JSY, Chan MY, Wong RCC, Chai P, Chan ACY, Sharma VK, Yeo LLL, Sia CH, Ong JJY. Myocardial infarction, stroke and cardiovascular mortality among migraine patients: a systematic review and meta-analysis. J Neurol 2022. [PMID: 34997286 DOI: 10.1007/s00415-021-10930-x] [Reference Citation Analysis]
16 Goadsby PJ, Tepper SJ, Watkins PB, Ayele G, Miceli R, Butler M, Severt L, Finnegan M, Szegedi A, Trugman JM, Jakate A. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults. Cephalalgia 2019;39:1753-61. [PMID: 31537107 DOI: 10.1177/0333102419869918] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
17 Vandenbussche N, Goadsby PJ. The discovery and development of inhaled therapeutics for migraine. Expert Opin Drug Discov 2019;14:591-9. [PMID: 30924698 DOI: 10.1080/17460441.2019.1598373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Marmura MJ, Hou A. Inpatient Management of Migraine. Neurol Clin 2019;37:771-88. [PMID: 31563232 DOI: 10.1016/j.ncl.2019.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Ong JJY, Patnaik D, Chan YC, Simon O, Finkelstein EA. Economic burden of migraine in Singapore. Cephalalgia Reports 2020;3:251581632090824. [DOI: 10.1177/2515816320908241] [Reference Citation Analysis]
20 Tfelt-hansen P, Diener H, Steiner TJ. Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review. Cephalalgia 2020;40:122-6. [DOI: 10.1177/0333102419877663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Vila-Pueyo M, Strother LC, Kefel M, Goadsby PJ, Holland PR. Divergent influences of the locus coeruleus on migraine pathophysiology. Pain 2019;160:385-94. [PMID: 30371556 DOI: 10.1097/j.pain.0000000000001421] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
22 Scott LJ. Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache. Drugs 2020;80:893-904. [PMID: 32504377 DOI: 10.1007/s40265-020-01329-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Close LN, Eftekhari S, Wang M, Charles AC, Russo AF. Cortical spreading depression as a site of origin for migraine: Role of CGRP. Cephalalgia. 2019;39:428-434. [PMID: 29695168 DOI: 10.1177/0333102418774299] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
24 Melinyshyn AN, Amoozegar F. Cannabinoid Use in a Tertiary Headache Clinic: A Cross-Sectional Survey. Can J Neurol Sci 2021;:1-10. [PMID: 34511153 DOI: 10.1017/cjn.2021.215] [Reference Citation Analysis]
25 Leone M. Evidence mounts for anti-CGRP treatment in cluster headache. Nat Rev Neurol 2018;14:636-7. [DOI: 10.1038/s41582-018-0063-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK, Terwindt GM, Goadsby PJ. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. Eur J Neurol 2020;27:609-18. [PMID: 31692188 DOI: 10.1111/ene.14114] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
27 Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, Tessitore A, Tedeschi G. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 2020;21:69. [PMID: 32517693 DOI: 10.1186/s10194-020-01143-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
28 Dolati S, Rikhtegar R, Mehdizadeh A, Yousefi M. The Role of Magnesium in Pathophysiology and Migraine Treatment. Biol Trace Elem Res 2020;196:375-83. [PMID: 31691193 DOI: 10.1007/s12011-019-01931-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
29 Urits I, Yilmaz M, Charipova K, Gress K, Bahrum E, Swett M, Berger AA, Kassem H, Ngo AL, Cornett EM, Kaye AD, Viswanath O. An Evidence-Based Review of Galcanezumab for the Treatment of Migraine. Neurol Ther 2020;9:403-17. [PMID: 33010021 DOI: 10.1007/s40120-020-00214-3] [Reference Citation Analysis]